Diridavumab - Johnson & Johnson Innovative Medicine
Alternative Names: CR-6261; JNJ-54235025; mAb CR6261; Monoclonal antibody CR6261Latest Information Update: 10 Oct 2023
At a glance
- Originator Crucell
- Developer National Institute of Allergy and Infectious Diseases
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Influenza virus haemagglutinin glycoprotein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza A virus H1N1 subtype
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 03 Feb 2017 Janssen Pharmaceuticals withdraws prior to enrolment a phase I trial for Healthy volunteers in Japan (NCT02016066)
- 24 Jan 2017 Diridavumab is still in phase II trials for Influenza A virus H1N1 subtype in USA